<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126670</url>
  </required_header>
  <id_info>
    <org_study_id>NP1401</org_study_id>
    <nct_id>NCT02126670</nct_id>
  </id_info>
  <brief_title>ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promius Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promius Pharma, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether or not ACT01 is effective and tolerable
      alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with
      facial and/or scalp keratosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success at End of Study Visit</measure>
    <time_frame>up to Day 57</time_frame>
    <description>Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Irritation Score</measure>
    <time_frame>up to Day 57</time_frame>
    <description>Percentage of participants with moderate or severe overall irritation at end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>ACT01 plus Comp01</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT01 plus Comp02</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT01 plus Comp03</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT01 plus Comp04</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT01</intervention_name>
    <arm_group_label>ACT01 plus Comp01</arm_group_label>
    <arm_group_label>ACT01 plus Comp02</arm_group_label>
    <arm_group_label>ACT01 plus Comp03</arm_group_label>
    <arm_group_label>ACT01 plus Comp04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp01</intervention_name>
    <arm_group_label>ACT01 plus Comp01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp02</intervention_name>
    <arm_group_label>ACT01 plus Comp02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp03</intervention_name>
    <arm_group_label>ACT01 plus Comp03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp04</intervention_name>
    <arm_group_label>ACT01 plus Comp04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presence of actinic keratosis lesions on the face and/or scalp within a 25 cm2
             contiguous area containing at least four lesions that are non-hypertrophic and
             non-hyperkeratotic and not larger than 6 mm in longest diameter.

          2. Age 30-85 years, inclusive.

          3. Good general health as determined by investigator and supported by medical history and
             normal or not clinically significant abnormal vital signs (blood pressure and pulse).

        Exclusion Criteria:

          1. Severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological,
             hepatic, neurological, pancreatic, pulmonary or renal disease.

          2. Dermatologic conditions if present on the face such as acne, atopic dermatitis,
             seborrheic dermatitis, eczema, rosacea, or albinism.

          3. Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen
             plus ultraviolet A) therapy, or 5) UVB therapy to the intended treatment area within
             180 days prior to the Baseline Visit.

          4. Use of sun lamps or sun tanning beds or booths during the 14 days prior to the
             Baseline Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research, LLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services; Zoe Diana Draelos, MD</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ACT01 Plus Comp01</title>
          <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
ACT01
Comp01</description>
        </group>
        <group group_id="P2">
          <title>ACT01 Plus Comp02</title>
          <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
ACT01
Comp02</description>
        </group>
        <group group_id="P3">
          <title>ACT01 Plus Comp03</title>
          <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
ACT01
Comp03</description>
        </group>
        <group group_id="P4">
          <title>ACT01 Plus Comp04</title>
          <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
ACT01
Comp04</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACT01 Plus Comp01</title>
          <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
ACT01
Comp01</description>
        </group>
        <group group_id="B2">
          <title>ACT01 Plus Comp02</title>
          <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
ACT01
Comp02</description>
        </group>
        <group group_id="B3">
          <title>ACT01 Plus Comp03</title>
          <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
ACT01
Comp03</description>
        </group>
        <group group_id="B4">
          <title>ACT01 Plus Comp04</title>
          <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
ACT01
Comp04</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="11.08"/>
                    <measurement group_id="B2" value="64.4" spread="9.78"/>
                    <measurement group_id="B3" value="66.5" spread="8.94"/>
                    <measurement group_id="B4" value="66.9" spread="8.28"/>
                    <measurement group_id="B5" value="65.5" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success at End of Study Visit</title>
        <description>Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions</description>
        <time_frame>up to Day 57</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>ACT01 Plus Comp01</title>
            <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
ACT01
Comp01</description>
          </group>
          <group group_id="O2">
            <title>ACT01 Plus Comp02</title>
            <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
ACT01
Comp02</description>
          </group>
          <group group_id="O3">
            <title>ACT01 Plus Comp03</title>
            <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
ACT01
Comp03</description>
          </group>
          <group group_id="O4">
            <title>ACT01 Plus Comp04</title>
            <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
ACT01
Comp04</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success at End of Study Visit</title>
          <description>Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions</description>
          <population>Per protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="47.8" upper_limit="85.5"/>
                    <measurement group_id="O2" value="65.2" lower_limit="45.8" upper_limit="84.7"/>
                    <measurement group_id="O3" value="76.0" lower_limit="59.3" upper_limit="92.7"/>
                    <measurement group_id="O4" value="66.7" lower_limit="47.8" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritation Score</title>
        <description>Percentage of participants with moderate or severe overall irritation at end of treatment.</description>
        <time_frame>up to Day 57</time_frame>
        <population>Overall irritation</population>
        <group_list>
          <group group_id="O1">
            <title>ACT01 Plus Comp01</title>
            <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
ACT01
Comp01</description>
          </group>
          <group group_id="O2">
            <title>ACT01 Plus Comp02</title>
            <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
ACT01
Comp02</description>
          </group>
          <group group_id="O3">
            <title>ACT01 Plus Comp03</title>
            <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
ACT01
Comp03</description>
          </group>
          <group group_id="O4">
            <title>ACT01 Plus Comp04</title>
            <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
ACT01
Comp04</description>
          </group>
        </group_list>
        <measure>
          <title>Irritation Score</title>
          <description>Percentage of participants with moderate or severe overall irritation at end of treatment.</description>
          <population>Overall irritation</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="52.0"/>
                    <measurement group_id="O4" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ACT01 Plus Comp01</title>
          <description>ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
ACT01
Comp01</description>
        </group>
        <group group_id="E2">
          <title>ACT01 Plus Comp02</title>
          <description>ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
ACT01
Comp02</description>
        </group>
        <group group_id="E3">
          <title>ACT01 Plus Comp03</title>
          <description>ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
ACT01
Comp03</description>
        </group>
        <group group_id="E4">
          <title>ACT01 Plus Comp04</title>
          <description>ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
ACT01
Comp04</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Promius Pharma, LLC</organization>
      <phone>609-282-1476</phone>
      <email>kgulbronson@promiuspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

